Duchenne muscular dystrophy (DMD) is an X linked progressive muscle disease caused by mutations in DMD gene leading to a lack od functional protein dystrophin. Duchenne (DMD) and Becker (BMD) muscular dystrophies are the most common childhood dystrophies. They are allelic diseases caused by gene mutation at the same locus but what distinguishes them are milder clinical picture and better prognosis in Becker's muscular dystrophy. The first clinical signs of this disease appear around ages 2 and 3 as delayed motor skills including speech development, clumsiness and frequent falls, and elevated levels of liver enzymes are usually found in laboratory tests as a coincidental finding in patients with acute usually respiratory infection . The disease advances especially around the age of 7 to immobility and wheelchair dependency , (non)invasive ventilation necessity before the age of 20 and premature death in second or third decade of life. Regarding the progressiveness of this disease, it's contemporary care and treatment are comprehensive and include intertwining of multiple medical specialties. Multidisciplinary treatment team of DMD inculdes a pediatrician, a neuropediatrician, a cardiologist, a pulmologist, a physiatrist, an orthopedic surgeon, a gastroenterologist and a psychologist. Therapy possibilities are corticosteroids, angiotensin convertase inhibitor and gene and molecular therapy but the majority of the possible treatments is still in research phases. Standard care of DMD patients includes therapeutic procedures, drugs and ASOs. Antisense oligonucleotide therapy (ataluren/Translarna) is approved in Croatia and is applied in those patients with nonsense premature stop-codon mutation. Other drug researches are being conducted for drugs which would target other gene regions and would potentialy be used for treating the rest of the affected population. DMD is still not curable but the therapy achieves slowing of disease progresion, improves quality of life and prolongs the life of the patients.